LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections
July 05, 2022 07:55 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in Wisconsin
July 01, 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Announces Management Cease Trade Order
June 30, 2022 17:32 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces, further to its news release on June 28, 2022, the...
LexaGene Files Form 10 Registration Statement with the SEC and Announces a Delay in Filing Year-End Annual Canadian Financial Filings
June 28, 2022 18:46 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces that it has filed an initial registration statement with...
LexaGene Announces Multi-System Purchase from a Large Market Leader in Animal Health
May 25, 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Successfully Completes CRADA with US Army
May 03, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Announces Multi-System Purchase from a Corporate Veterinary Reference Laboratory
April 25, 2022 08:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Announces Advancements to its Sample Preparation Cartridge for the Veterinary Market
March 29, 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System, a...
LexaGene Announces Closing of Second Tranche of Investment by Strategic Institutional Investor
February 18, 2022 12:25 ET
|
LexaGene Holdings Inc
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BEVERLY, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)...
LexaGene Announces $6.4 Million Investment by Strategic Institutional Investor
February 08, 2022 08:20 ET
|
LexaGene Holdings Inc
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BEVERLY, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)...